Solid Lipid Nanoparticles Carrying Temozolomide for Melanoma Treatment. Preliminary In Vitro and In Vivo Studies

Aim: To develop an innovative delivery system for temozolomide (TMZ) in solid lipid nanoparticles (SLN), which has been preliminarily investigated for the treatment of melanoma. Materials and Methods: SLN-TMZ was obtained through fatty acid coacervation. Its pharmacological effects were assessed and...

Descripción completa

Detalles Bibliográficos
Autores principales: Clemente, Nausicaa, Ferrara, Benedetta, Gigliotti, Casimiro Luca, Boggio, Elena, Capucchio, Maria Teresa, Biasibetti, Elena, Schiffer, Davide, Mellai, Marta, Annovazzi, Laura, Cangemi, Luigi, Muntoni, Elisabetta, Miglio, Gianluca, Dianzani, Umberto, Battaglia, Luigi, Dianzani, Chiara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5855544/
https://www.ncbi.nlm.nih.gov/pubmed/29364157
http://dx.doi.org/10.3390/ijms19020255
Descripción
Sumario:Aim: To develop an innovative delivery system for temozolomide (TMZ) in solid lipid nanoparticles (SLN), which has been preliminarily investigated for the treatment of melanoma. Materials and Methods: SLN-TMZ was obtained through fatty acid coacervation. Its pharmacological effects were assessed and compared with free TMZ in in vitro and in vivo models of melanoma and glioblastoma. Results: Compared to the standard free TMZ, SLN-TMZ exerted larger effects, when cell proliferation of melanoma cells, and neoangiogeneis were evaluated. SLN-TMZ also inhibited growth and vascularization of B16-F10 melanoma in C57/BL6 mice, without apparent toxic effects. Conclusion: SLN could be a promising strategy for the delivery of TMZ, allowing an increased stability of the drug and thereby its employment in the treatment of aggressive malignacies.

Ejemplares similares